Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers.
Beauvais D, Labeyrie C, Cauquil C, Francou B, Eliahou L, Not A, Echaniz-Laguna A, Adam C, Slama MS, Benmalek A, Leonardi L, Rouzet F, Adams D, Algalarrondo V, Beaudonnet G.
Beauvais D, et al. Among authors: adams d.
J Neurol Neurosurg Psychiatry. 2024 May 14;95(6):489-499. doi: 10.1136/jnnp-2023-332180.
J Neurol Neurosurg Psychiatry. 2024.
PMID: 37875336
Free PMC article.